Literature DB >> 677863

Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin.

T Bergan.   

Abstract

Bacampicillin is a new oral prodrug which is rapidly converted to ampicillin during absorption from the gastrointestinal tract. High serum peaks of ampicillin are obtained. Bacampicillin orally was compared pharmacokinetically with parenteral ampicillin (intravenously and intramuscularly). A cross-over study on healthy volunteers showed that ampicillin concentrations after equimolar doses of bacampicillin orally and ampicillin intramuscularly were of the same order. The mean of the individual peak values (regardless of time of occurrence) after a dose of 800 mg of bacampicillin was 13.1 +/- 3.8 mug/ml. Absorption rates of the two doses were similar, as were their distribution volumes (approximately 25% of the body weight). Bioavailability was 87% for bacampicillin, compared to 71% for ampicillin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 677863      PMCID: PMC352373          DOI: 10.1128/AAC.13.6.971

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  SODIUM AMPICILLIN: ABSORPTION AND EXCRETION OF INTRAMUSCULAR AND INTRAVENOUS DOSES IN NORMAL YOUNG MEN.

Authors:  T C EICKHOFF; J W KISLAK; M FINLAND
Journal:  Am J Med Sci       Date:  1965-02       Impact factor: 2.378

2.  [EXPERIMENTAL AND CLINICAL STUDIES ON THE PARENTERAL USE OF AMPICILLIN].

Authors:  P NAUMANN
Journal:  Dtsch Med Wochenschr       Date:  1965-06-11       Impact factor: 0.628

3.  Absorption and excretion of "Penbritin".

Authors:  E T KNUDSEN; G N ROLINSON; S STEVENS
Journal:  Br Med J       Date:  1961-07-22

4.  Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects.

Authors:  W J Jusko; G P Lewis; G W Schmitt
Journal:  Clin Pharmacol Ther       Date:  1973 Jan-Feb       Impact factor: 6.875

5.  Antibacterial action of "broad-spectrum" penicillins, cephalosporins and other antibiotics against Gram-negative bacilli isolated from bacteremic patients.

Authors:  N H Steigbigel; C E McCall; C W Reed; M Finland
Journal:  Ann N Y Acad Sci       Date:  1967-09-27       Impact factor: 5.691

6.  Microbiological assay of josamycin.

Authors:  T Bergan; B Oydvin
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1972

7.  Comparison of ampicillin and hetacillin pharmacokinetics in man.

Authors:  W J Jusko; G P Lewis
Journal:  J Pharm Sci       Date:  1973-01       Impact factor: 3.534

Review 8.  Practical concepts of drug absorption, distribution and loss.

Authors:  C MacLeod; H Rabin; R Ogilvie; J Ruedy; M Caron; D Zarowny; R O Davies
Journal:  Can Med Assoc J       Date:  1974-08-17       Impact factor: 8.262

9.  Pharmacokinetics of pivampicillin and ampicillin in man.

Authors:  J C Loo; E L Foltz; H Wallick; K C Kwan
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

10.  Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin, and amoxycillin.

Authors:  J Sjövall; L Magni; T Bergan
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

View more
  14 in total

1.  Potential improvement in the shelf life of parenterals using the prodrug approach: bacampicillin and talampicillin hydrolysis kinetics and utilization time.

Authors:  N A Nguyen; L M Mortada; R E Notari
Journal:  Pharm Res       Date:  1988-05       Impact factor: 4.200

2.  Potential improvement in shelf life using the prodrug approach. II. A systematic examination of kinetic requirements.

Authors:  N A Nguyen; R E Notari
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

3.  Clinical pharmacological evaluation of aminopenicillins.

Authors:  H Mattie; P L Meenhorst
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 4.  Pharmacokinetics of bacampicillin tablets in adults.

Authors:  W A Craig
Journal:  Bull N Y Acad Med       Date:  1983-06

5.  Sequential parenteral oral antibiotic therapy for serious infections.

Authors:  J D Nelson
Journal:  Bull N Y Acad Med       Date:  1983-06

6.  Bacampicillin in therapy of lower respiratory infections.

Authors:  W Mogabgab; B Pollock; B Holmes; R Beville
Journal:  Bull N Y Acad Med       Date:  1983-06

7.  Comparative clinical pharmacology of bacampicillin and high oral doses of ampicillin.

Authors:  L Magni; J Sjövall; E Syvälahti
Journal:  Infection       Date:  1978       Impact factor: 3.553

8.  Bacampicillin to treat non-gonococcal urethritis in men: pilot study.

Authors:  C T Lee; K B Lim; T Thirumoorthy; M Nadarajah
Journal:  Genitourin Med       Date:  1989-01

Review 9.  Studies on aminopenicillin developments. Proceedings of a symposium. Concluding remarks.

Authors:  T Bergan
Journal:  Infection       Date:  1979       Impact factor: 3.553

10.  Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man.

Authors:  M Ehrnebo; S O Nilsson; L O Boréus
Journal:  J Pharmacokinet Biopharm       Date:  1979-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.